Rapid Reactions is a video series that provides commentary from key experts summarizing data released at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) focused on gastric, gastroesophageal, and esophageal cancer. Please join Minsig Choi, MD, from Stonybrook University Cancer Center, as he discusses the following 3 pivotal presentations from ASCO-GI 2022:
- Updated results of the CheckMate-649 study indicated that nivolumab plus chemotherapy continued to demonstrate clinically meaningful improvement in efficacy with longer follow-up, with no emergence of new safety issues
- Results of the multicohort phase 1/2 KRYSTAL-1 study indicated that adagrasib monotherapy was well tolerated and demonstrated encouraging clinical activity in pretreated patients with GI tumors harboring a KRAS G12C mutation
- Updated results of the DESTINY-Gastric01 trial indicated that T-DXd therapy continued to demonstrate overall survival benefit compared with chemotherapy, accompanied by a manageable safety profile, in previously treated patients with HER2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma
